

July 13, 2017

BSE Limited
Corporate Relationship Department
1st floor, New Trading Ring
Rotunda Building, P J Towers
Dalal Street, Fort
Mumbai - 400 001

**Sub: Submission of Audited Financials in the revised format as per Schedule III of
the Companies Act, 2013**

Dear Sir/Madam,

We refer to our letter dated May 26, 2017, wherein we had submitted the standalone and consolidated financial results of the Company for the quarter and the year ended March 31, 2017 ("the financial results") which were approved and taken on record at the meeting of the Board of Directors of the Company held on May 26, 2017.

We now refer to you email dated July 10, 2017 and as a measure of clarification, we submit herewith the said financial results in the revised format. Kindly note that the figures as reported earlier, remain unchanged.

We confirm that M/s SNB Associates, Statutory Auditors of the Company, have issued Audit report on the standalone and consolidated financial results and the same has already been submitted.

Thanking you,
Yours faithfully,



L Chandrasekar
Executive VP – Finance & Secretary

Encl.: a/a


CC: National Stock Exchange of India Ltd.
Listing Department
Exchange Plaza, 5th Floor,
Plot No: C/1, G - Block,
Bandra - Kurla Complex
Bandra (East), Mumbai - 400051

BSE Limited had vide its email dated July 10, 2017 informed us to submit financial results as per format prescribed in Schedule III of the Companies Act, 2013 for March 31, 2017. In this regard, we have uploaded the financial results in the revised format as per Schedule III of the Companies Act, 2013 on BSE Portal. To comply with the requirements, we are also uploading the results on NSE Portal.

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2017

Rs. lakhs

Sl. No.	Particulars	Three months ended			Stand alone for the year ended		Consolidated for the year ended	
		31/03/2017 (Refer Note 9)	31/12/2016 (Unaudited)	31/03/2016 (Refer Note 9)	31/03/2017 (Audited)	31/03/2016 (Audited)	31/03/2017 (Audited)	31/03/2016 (Audited)
I	Revenue from Operations	20,488.40	17,998.28	20,943.92	76,628.76	88,988.56	80,743.66	88,398.62
II	Other Income	856.49	623.19	915.76	1,479.68	916.69	1,479.97	2,490.58
III	Total Revenue (I) + (II)	21,344.89	18,621.47	21,859.68	78,108.44	89,905.25	82,223.63	90,889.20
IV	Expenses							
	Cost of Materials consumed	9,254.94	9,498.12	7,133.25	33,954.60	36,701.01	34,082.37	37,051.89
	Purchases of Stock-in-Trade	35.13	182.92	20.68	2,601.75	3,701.23	2,601.75	3,701.23
	Changes in inventories of Finished goods, Work-in-progress and Stock-in-trade	345.04	(2,207.38)	1,820.81	190.04	1,528.82	2,661.58	(656.66)
	Employee benefits expense	1,755.47	1,957.54	1,683.87	7,550.65	8,263.08	8,031.44	8,680.93
	Finance costs	12,125.05	6,942.97	7,134.38	33,110.24	29,423.18	33,110.89	29,424.49
	Depreciation and Amortisation expense	3,492.36	3,524.06	3,504.98	13,941.89	14,341.22	14,101.58	14,526.65
	Other Expenses	8,533.41	5,041.36	5,477.72	22,655.26	19,844.52	24,216.04	22,542.48
	Total Expenses	35,541.40	24,939.59	26,775.69	1,14,004.43	1,13,803.06	1,18,805.65	1,15,271.01
V	Profit / (Loss) from Operations before Exceptional and Extra-ordinary Items and tax (III - IV)	(14,196.51)	(6,318.12)	(4,916.01)	(35,895.99)	(23,897.81)	(36,582.02)	(24,381.81)
VI	Exceptional Item - Gain/(Loss)	(5,775.29)	(999.45)	(1,362.31)	(8,645.59)	(5,254.53)	(8,645.59)	(5,254.53)
VII	Profit/(Loss) before Extra-ordinary items and Tax (V - VI)	(19,971.80)	(7,317.57)	(6,278.32)	(44,541.58)	(29,152.34)	(45,227.61)	(29,636.34)
VIII	Extra-ordinary Items - Gain/(Loss) (net of tax)	-	-	-	(8,625.85)	-	(8,625.85)	-
IX	Profit before tax (VII - VIII)	(19,971.80)	(7,317.57)	(6,278.32)	(53,167.43)	(29,152.34)	(53,853.46)	(29,636.34)
X	Tax expense - Deferred Tax	(1,186.49)	(1,219.68)	96.00	(4,804.32)	(1,725.07)	(4,804.32)	(1,725.07)
XI	Profit/(Loss) for the period from continuing operations (IX - X)	(18,785.31)	(6,097.89)	(6,374.32)	(48,363.11)	(27,427.27)	(49,049.14)	(27,911.27)
XII	Profit/(Loss) for the period from discontinuing operations	-	-	-	-	-	-	-
XIII	Net Profit/(Loss) for the period (XI - XII)	(18,785.31)	(6,097.89)	(6,374.32)	(48,363.11)	(27,427.27)	(49,049.14)	(27,911.27)
XIV	Earnings per equity share (EPS) before extra-ordinary items (of Rs.10 each)							
	- Basic Rs.*	(21.12)	(6.85)	(7.32)	(44.67)	(31.51)	(45.44)	(32.07)
	- Diluted Rs.*	(21.12)	(6.85)	(7.32)	(44.67)	(31.51)	(45.44)	(32.07)
	Earnings per equity share (EPS) after extra-ordinary item (of Rs.10 each)							
	- Basic Rs.*	(21.12)	(6.85)	(7.32)	(54.36)	(31.51)	(55.13)	(32.07)
	- Diluted Rs.*	(21.12)	(6.85)	(7.32)	(54.36)	(31.51)	(55.13)	(32.07)
	* EPS for the period (not annualised)							
	See accompanying note to the Financial Results							



STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2017

- 1 The above audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 26, 2017.
- 2 The Company is operating in a single segment (i.e) "Pharmaceuticals".
- 3 Exceptional items for quarter/year ended March 31, 2017 represents amortisation of exchange loss on restatement of Foreign currency loans amounting to Rs.441.19 Lakhs / Rs.3312.29 Lakhs and Provision for contingencies relating to transferred business amounting to Rs.5333.30 Lakhs (Amortisation of exchange loss during corresponding previous quarter/year ended March 31,2016 Rs.1362.31 Lakhs and Rs.5254.53 Lakhs)
- 4 The Company had exercised the option provided under the Companies (Accounting Standards) Amendment Rules, 2006 dated March 31, 2009. The Ministry of Corporate affairs vide notification dated 29/12/2011 has extended the amortisation of gains or losses arising on reporting of foreign currency monetary items over the balance period of such long term asset/liability. Accordingly exchange loss on long term foreign currency loans have been amortised over the balance period of such loans. The amount remaining to be amortised in the financial statements as at March 31, 2017 on account of exercising the above option is Rs.5498.78 Lakhs.
- 5 Interest expenses for the quarter/year ended March 31, 2017 is net of interest earned Rs.298.40 Lakhs and Rs.1480.33 Lakhs respectively (Corresponding previous quarter/ year Rs.484.92 Lakhs and Rs. 1876.42 Lakhs). Interest for the quarter includes an amount of Rs.5093.90 Lakhs, being claims made by lending Banks for prior years.
- 6 Other income for the quarter / year ended March 31, 2017 includes recovery of excess remuneration paid to Managing Director amounting to Rs.428.55 Lakhs and Rs.1045.27 Lakhs respectively due to non receipt of approval from Central Government.
- 7 Extra-ordinary item for the year ended March 31, 2017 represents write-off of hold back money and inventory related to Transfer of Penam and Penicillin Business during July 2014.
- 8 The auditors have observed matters relating to recovery of certain advances paid to suppliers, non-provision of diminution in value of investment in a foreign R&D subsidiary, non provision of amount due from marketing subsidiary and non receipt of confirmation from few banks. The Corporate Debt Restructuring scheme has been implemented in July 2014. Due to financial constraints, the Company was not able to take delivery of materials/capital goods. The management is confident that it would be able to take delivery of these materials/capital goods in due course, based on its performance. As far as the diminution in value of investments is concerned, the Management is confident that the value of intellectual property of molecules held by the foreign subsidiary will be more than the investment. In respect of dues from the marketing subsidiary, the Company is exporting and selling profitable products through its marketing subsidiary and the profit generated by the marketing subsidiary from the operations will be available for settlement of past dues. In view of the delay in payment of interest and principal, few banks have not provided balance confirmation. However the interest on the outstanding with such banks has been provided at the applicable rates. Hence the Board of Directors considering the explanation given by the Management is of the opinion that the observations made by the auditors will not have material impact on the financials. The auditors have previously qualified non-impairment of investment in and non-provision of dues receivable from an R&D subsidiary amounting to Rs.128.24 Cr. The Company has obtained valuation of the molecule held by the subsidiary from a reputed valuer, the value of which adequately covers the entire exposure of the Company towards the subsidiary.
- 9 The Statement includes the results for the quarter ended March 31, 2017 and March 31, 2016 being the balancing figure between audited figures in respect of the full financial year and the published year to date unaudited figures up to the third quarter of the respective financial year which were subject to limited review by auditors.
- 10 Previous period figures have been regrouped wherever necessary.

For and on behalf of the Board


 K. Raghavendra Rao
 Managing Director
Place : Chennai
Date : May 26, 2017



Orchid Pharma Ltd.

STATEMENT OF ASSETS AND LIABILITIES

Rs. Lakhs

	Particulars	Stand alone (Audited)		Consolidated (Audited)	
		As at 31/03/2017	As at 31/03/2016	As at 31/03/2017	As at 31/03/2016
A	EQUITY AND LIABILITIES				
1	Shareholders' funds				
	(a) Share Capital	8,896.43	8,896.43	8,896.43	8,896.43
	(b) Reserves and Surplus	(35,279.74)	8,217.04	(47,663.03)	(3,991.94)
	Sub-total- Shareholders' funds	(26,383.31)	17,113.47	(38,766.60)	4,904.49
2	Non-current liabilities				
	(a) Long-term borrowings	2,14,236.58	2,37,753.66	2,14,236.58	2,37,753.65
	(b) Deferred tax liabilities (net)	4,609.91	9,414.23	4,609.91	9,414.23
	(c) Long-term provisions	206.67	373.09	206.67	373.09
	Sub-total- Non-current liabilities	2,19,053.16	2,47,540.98	2,19,053.16	2,47,540.97
3	Current liabilities				
	(a) Short-term borrowings	59,952.38	63,362.38	59,952.38	63,379.07
	(b) Trade payables	41,268.12	35,308.80	43,351.73	37,426.63
	(c) Other current liabilities	49,461.40	28,505.36	49,485.42	28,534.46
	(d) Short-term provisions	4,043.57	4,421.59	4,043.57	4,421.59
	Sub-total-Current liabilities	1,54,725.47	1,31,598.13	1,56,833.10	1,33,761.75
	TOTAL-EQUITY AND LIABILITIES	3,47,395.32	3,96,252.58	3,37,119.66	3,86,207.21
B	ASSETS				
1	Non-current assets				
	(a) Fixed assets	1,69,001.49	1,82,076.30	1,78,485.19	1,91,723.27
	(b) Non-current investments	12,466.09	12,464.72	96.19	81.19
	(c) Long-term loans and advances	55,955.83	56,598.08	55,955.83	56,581.90
	(d) Other non-current assets	13,348.92	12,701.07	13,348.92	12,701.07
	Sub-total- Non-current assets	2,50,772.33	2,63,840.17	2,47,886.13	2,61,087.43
2	Current assets				
	(a) Inventories	19,745.37	21,034.45	21,125.13	24,184.91
	(b) Trade receivables	25,252.49	37,544.03	20,910.78	31,007.45
	(c) Cash and cash equivalents	25,604.33	31,311.22	25,706.40	31,494.01
	(d) Short-term loans and advances	26,020.80	32,022.71	21,491.22	27,933.41
	(e) Other Current Assets	-	10,500.00	-	10,500.00
	Sub-total-current assets	96,622.99	1,32,412.41	89,233.53	1,25,119.78
	TOTAL ASSETS	3,47,395.32	3,96,252.58	3,37,119.66	3,86,207.21

For and on behalf of the Board

K. Raghavendra Rao
Managing Director

Place : Chennai
Date : May 26, 2017

